IL33 and breast cancer: The serum levels of IL-33 and VEGF in all breast cancer patients taken together, ER-positive breast cancer patients, and ER-negative breast cancer patients were significantly higher than those of the control group (IL-33: 105.5 ± 16.0 pg/mL, 162.0 ± 39.2 pg/mL, 306.0 ± 140.8 pg/mL compared with 30.7 ± 3.3 pg/mL P < 0.05,each; Figure 1B; VEGF: 257.6 ± 14.6 pg/mL, 248.5 ± 16.5 pg/mL, 263.1 ± 29.8 pg/mL compared with 93.0 ± 8.6 pg/mL P < 0.05,each; Figure 1C).